Patents Assigned to CVie Therapeutics Limited
  • Patent number: 11730746
    Abstract: Disclosed are compounds of formula (I), wherein X, Y, Z are annular atoms comprised in a five-membered carbocyclic or heterocyclic ring, selected from the group consisting of CH, NH, N, O, S; said carbocyclic or heterocyclic ring being optionally substituted with amino (C1-C4) linear or branched alkyl or guanidine or guanidino (C1-C4) linear or branched alkyl; with the proviso that the heterocycle ring is not furyl; n is 0 or 1; R is H or OH; the dotted line represents an optional double bond C?C; the thick line represents a bond in the ? configuration; the wavy line represents a bond both in the ? and ? configuration; their enantiomeric and/or diastereomeric mixtures, their pharmaceutically acceptable salts, their solvates, hydrates; their metabolite and metabolic precursors. The compounds of formula (I) are for use as medicaments, in particular for the treatment of acute or chronic heart failure. Oral administration is also possible.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: August 22, 2023
    Assignee: CVie Therapeutics Limited
    Inventors: Alberto Cerri, Giuseppe Bianchi, Patrizia Ferrari, Mara Ferrandi, Paolo Barassi, Antonio Zaza, Marcella Rocchetti, Carlotta Ronchi, Shih-Che Hsu
  • Publication number: 20210283147
    Abstract: Disclosed are compounds of formula (I), wherein X, Y, Z are annular atoms comprised in a five-membered carbocyclic or heterocyclic ring, selected from the group consisting of CH, NH, N, O, S; said carbocyclic or heterocyclic ring being optionally substituted with amino (C1-C4) linear or branched alkyl or guanidine or guanidino (C1-C4) linear or branched alkyl; with the proviso that the heterocycle ring is not furyl; n is 0 or 1; R is H or OH; the dotted line represents an optional double bond C?C; the thick line represents a bond in the ? configuration; the wavy line represents a bond both in the ? and ? configuration; their enantiomeric and/or diastereomeric mixtures, their pharmaceutically acceptable salts, their solvates, hydrates; their metabolite and metabolic precursors. The compounds of formula (I) are for use as medicaments, in particular for the treatment of acute or chronic heart failure. Oral administration is also possible.
    Type: Application
    Filed: July 17, 2019
    Publication date: September 16, 2021
    Applicant: CVie Therapeutics Limited
    Inventors: Alberto CERRI, Giuseppe BIANCHI, Patrizia FERRARI, Mara FERRANDI, Paolo BARASSI, Antonio ZAZA, Marcella ROCCHETTI, Carlotta RONCHI, Shih-Che HSU